Actively Recruiting
NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy
Led by NoNO Inc. · Updated on 2025-07-15
600
Participants Needed
9
Research Sites
112 weeks
Total Duration
On this page
Sponsors
N
NoNO Inc.
Lead Sponsor
U
University of Calgary
Collaborating Sponsor
AI-Summary
What this Trial Is About
ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632). This trial is a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive trial. A total of up to 600 male and female participants aged ≥ 18 to ≤ 90 years harboring an acute ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular thrombectomy therapy will be enrolled within 4.5 hours of stroke onset/last known well.
CONDITIONS
Official Title
NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed or suspected acute ischemic stroke selected for intravenous thrombolysis.
- Stroke onset (last-known-well) to randomization within 4.5 hours.
- Age between 18 and 90 years.
- Disabling stroke with baseline NIH Stroke Score greater than 5.
- Confirmed or suspected symptomatic anterior circulation intracranial occlusion, including tandem extracranial carotid and intracranial occlusions.
- Independent in daily activities before stroke as judged by the enrolling physician; not requiring nursing care.
- Consent obtained according to national laws and ethics committee requirements.
You will not qualify if you...
- Large extent early ischemic changes or infarct in the affected brain area on imaging.
- Any intracranial hemorrhage seen on qualifying imaging.
- Unlikely to receive study drug before arterial puncture if selected for endovascular thrombectomy.
- Known or suspected pregnancy or lactation.
- Systolic blood pressure below 90 mmHg.
- Previous receipt of NoNO-42, including prior participation in this trial.
- Severe other illness with life expectancy under 90 days or likely to prevent completing 90-day follow-up.
- Resident in long term care facility or prisoner.
- Participation in another clinical trial involving drugs, devices, neuro-interventions, or surgery not considered standard care within 30 days before enrollment.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
University of Calgary - Foothills Medical Centre
Calgary, Alberta, Canada, T2N 2T9
Actively Recruiting
2
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2B7
Actively Recruiting
3
Vancouver General Hospital
Vancouver, British Columbia, Canada, V5M 1Z9
Actively Recruiting
4
University of Manitoba
Winnipeg, Manitoba, Canada, R3E 3P5
Actively Recruiting
5
Hamilton General Hospital
Hamilton, Ontario, Canada, L8L 2X2
Actively Recruiting
6
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada, K1H 8L6
Actively Recruiting
7
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Actively Recruiting
8
Unity Health Toronto, St. Michael's Hospital
Toronto, Ontario, Canada, M5B 1W8
Actively Recruiting
9
Royal University Hospital
Saskatoon, Saskatchewan, Canada, S7N 0W8
Actively Recruiting
Research Team
M
Michael Tymianski, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here